Package 0228-3154-03

{"route": ["SUBLINGUAL"], "spl_id": "f8429e6b-f73d-4f29-8e2e-f8910cfba41d", "openfda": {"unii": ["5Q187997EE", "56W8MW3EN1"], "rxcui": ["351266", "351267"], "spl_set_id": ["6cccf229-9611-4b6f-8f1b-acc8ff1ed3f8"], "manufacturer_name": ["Actavis Pharma, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET in 1 BOTTLE (0228-3154-03)", "package_ndc": "0228-3154-03", "marketing_start_date": "20130304"}], "brand_name": "Buprenorphine and Naloxone", "product_id": "0228-3154_f8429e6b-f73d-4f29-8e2e-f8910cfba41d", "dosage_form": "TABLET", "pharm_class": ["Opioid Antagonist [EPC]", "Opioid Antagonists [MoA]", "Partial Opioid Agonist [EPC]", "Partial Opioid Agonists [MoA]"], "product_ndc": "0228-3154", "dea_schedule": "CIII", "generic_name": "Buprenorphine and Naloxone", "labeler_name": "Actavis Pharma, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Buprenorphine and Naloxone", "active_ingredients": [{"name": "BUPRENORPHINE HYDROCHLORIDE", "strength": "2 mg/1"}, {"name": "NALOXONE HYDROCHLORIDE DIHYDRATE", "strength": ".5 mg/1"}], "application_number": "ANDA091422", "marketing_category": "ANDA", "marketing_start_date": "20130304", "listing_expiration_date": "20271231"}